Hypertension Cardiovascular Diseases
Conditions
Interventions
This is a three-arm, parallel-group, randomized controlled clinical trial. Seventy-five hypertensive older adults of both sexes will be recruited and randomly assigned to three groups of 25 participan
Sponsors
Universidade Comunitária da Região de Chapecó
Instituto Federal do Paraná
Eligibility
Age
60 Years to No maximum
Inclusion criteria
Inclusion criteria: Individuals of both sexes; aged 60 years or older; who have not engaged in regular physical exercise for at least three months; diagnosed with arterial hypertension and undergoing regular treatment; medically cleared to practice physical exercise; and who agree to the proposed procedures and to sign the Informed Consent Form (ICF)
Exclusion criteria
Exclusion criteria: Individuals who use medications that could interfere with the intervention results; who fail to undergo any of the procedures required for the study; who present clinical conditions that contraindicate blood flow restriction exercise, such as uncontrolled blood pressure or peripheral cardiovascular disease; or who miss three consecutive sessions, or five or more non-consecutive sessions, during the intervention period
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood pressure: reduction in systolic and diastolic blood pressure, assessed through standardized measurement of resting blood pressure using validated equipment and a protocol recommended by current guidelines, with results expressed in mmHg and as absolute and percentage changes from baseline values. Assessments will be conducted during the pre-intervention period (baseline) and immediately at the end of the intervention period. An average reduction in systolic blood pressure of between 3 and 8 mmHg is expected compared to the control group, based on evidence available in the literature | — |
Secondary
| Measure | Time frame |
|---|---|
| Muscle strength: increase in muscle strength, assessed using the one-repetition maximum (1RM) test, performed according to a standardized protocol for the exercises evaluated, with results expressed in kilograms and as a percentage change from baseline values. Assessments will be conducted during the pre-intervention period (baseline) and immediately after the completion of the 16-week intervention. An increase in muscle strength of between 10% and 20% is expected compared to baseline values and the control group, based on evidence available in the literature.;Endothelial function: improvement in endothelial function, assessed through laboratory analysis of nitrite/nitrate (NOx) concentrations, endothelin-1 (ET-1), ICAM-1, VCAM-1, E-selectin, PAI-1, von Willebrand factor (vWF), and high-sensitivity C-reactive protein (hs-CRP), with results expressed in their respective units of measurement and as absolute and percentage changes from baseline values. Assessments will be conducted during the pre-intervention period (baseline) and immediately after the completion of the 16-week intervention. An increase in NOx concentrations and a reduction in the concentrations of ET-1, ICAM-1, VCAM-1, E-selectin, PAI-1, vWF, and hs-CRP are expected compared to baseline values and the control group, in accordance with evidence available in the literature;Muscle thickness: increase in the muscle thickness of the rectus femoris and biceps brachii, assessed using A-mode ultrasound with the BodyMetrix® system (IntelaMetrix Inc., Livermore, CA, USA) to identify the interfaces between adipose, muscle, and bone tissues and to noninvasively measure muscle thickness. Results will be expressed in millimeters (mm) and as absolute and percentage changes relative to baseline values. Assessments will be performed at standardized anatomical sites during the pre-intervention period (baseline) and immediately after completion of the 16-week intervention. An increase in muscle thickness of between 3% a | — |
Countries
BR
Contacts
Public ContactCezar Ribeiro
Instituto Federal do Paraná - Campus Palmas
Outcome results
None listed